Turkey will purchase 20 million COVID-19 Vaccines from China
Turkey will purchase 20 million COVID-19 Vaccines from China. Turkish Health Minister Fahrettin Koca stated in the Turkish Parliament that Turkey will sign a contract to purchase approximately 20 million doses of the COVID-19 vaccine from Beijing Kexing Zhongwei Biotechnology Co., Ltd. within a few days.
According to reports, Turkish Health Minister Koka stated at the Turkish Parliament’s budget report: “We will be able to purchase at least 10 million doses of Chinese vaccines in December. We want to increase this number and we will purchase the same amount in January next year. Vaccines.” He added: “This number may easily double, and this contract will be signed within a day or two.”
According to reports, in addition to China’s Kexing vaccine, Turkey is negotiating with Pfizer and BioNTech to purchase the COVID-19 vaccine. Pfizer and BioNTech said that their COVID-19 pneumonia vaccine will receive emergency authorization from the United States and Europe next month. The final test results show that the vaccine has a 95% success rate and no serious side effects.
Koka said that once the license is obtained, Turkey will negotiate the purchase of Pfizer’s vaccines. “If this is the case, the number that can be provided to Turkey is 1 million. We are now negotiating. Starting from January next year, it will gradually increase to 25 million.”
In August of this year, the Drugs and Medical Devices Agency of the Ministry of Health of Turkey approved the COVID-19 vaccine developed by Kexing to conduct a randomized, double-blind, and controlled third clinical study in Turkey. The trial design enrolled 13,000 people (including 1,200 medical staff), and the volunteers were adult healthy people aged 18 to 59 to verify the effectiveness of the vaccine.
On September 17, the Hajtepe University School of Medicine in Ankara, Turkey injected the first batch of volunteers with the COVID-19 vaccine. According to preliminary test results, Kexing’s COVID-19 vaccine can quickly trigger an immune response.
According to a peer-reviewed paper in the latest issue of the medical journal “The Lancet Infectious Diseases”, all four Chinese vaccines can trigger a rapid immune response, and the vaccine developed by China Kexing Company is compared with the current US drug maker Pfizer, The COVID-19 vaccine of companies such as Moderna is more suitable for vaccination in third world countries. According to reports, the coronavirus vaccine and four other experimental vaccines developed in China are currently undergoing late-stage trials to determine their effectiveness in preventing COVID-19 pneumonia.